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DEFINITIONS  
 
Conjugation                     The chemical attachment of a chelator molecule to an           
    antibody. 
Immunoconjugate             The resultant adduct of conjugation. 
Labeling   The tagging of a molecule with a radioactive isotope.  
Chelation                           The complexing of a metal ion with a multi-dentate ligand. 
Freeze-dried Cake             The dry product in the vial on completion of freeze-drying. 
UV-VIS   Ultraviolet – Visible spectrophotometer. 
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ABSTRACT 
 
Infectious and inflammatory diseases are the commonest cause of mortality around the 
world.  Rational diagnosis of infectious and inflammatory diseases is important for better 
disease management outcome.   
Nuclear Medicine procedure using radiopharmaceuticals gives both functional and         
anatomical information. The study objective was to formulate a ready use cold kit of hu-
man immunoglobulin IgG to be labeled with 99mTc for the diagnosis of infectious and 
inflammatory disease.  We used both the direct and indirect labeling method.   
We obtained better labeling efficiency for the directly labeled kit. 
 
Key words: 
Immunoglobulin G, infection, inflammation, kit formulation, Technetium-99m 
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1. INTRODUCTION  
1.1. Background information  
Infection and inflammation still remain the major cause of mortality and morbidity in most 
developing countries despite advances in treatment and diagnosis [1]  Appropriate diag-
nosis of infection and inflammation at an early stage is crucial to the     improvement of 
the efficiency of treatment and prognosis. Different diagnosis modalities such as ultra-
sound, computed tomography (CT), magnetic resonance (MRI), etc. have been used, 
which only gives anatomical sites of infection and inflammation foci.  Nuclear   medicine 
procedure using radiopharmaceuticals is invaluable in providing both anatomical and 
functional imaging of infection and inflammation information [2, 3]. 
Several radiopharmaceuticals have been developed, evaluated and clinically used to 
identify the site of infection and inflammation in a specific situation. These include    99mTc-
methylene diphosphonate (MDP), 67Ga citrate, radiolabeled leukocytes, FDG positron 
emission tomography, radiolabeled antimicrobial, radiolabeled antibacterial peptides, ra-
diolabeled monoclonal and polyclonal human immunoglobulin G (antibodies). However, 
none of them is an ideal radiopharmaceutical for the detection of infection and inflamma-
tion [4].  
Currently 99mTc labeled leukocyte radiopharmaceutical is accepted as a gold standard 
method for the detection of acute infection and inflammation foci. Unfortunately, the 
method has several disadvantages limiting its application. It requires a complex blood   
handling procedure that is a risk for contamination of a patient or personnel, additional 
facility, equipment, as well as trained experts. Furthermore, the accumulation of radioac-
tivity in non-target organs; 99mTc-HMPAO in bowel, and 99mTc nano-colloid in RES or-
gans gives false positive results. It is contraindicated in patients with neutropenia and 
infants, as it requires a large volume of blood for the procedure. Another limitation with 
this method is the condition that affects leukocyte harvesting and function resulting in 
poor image quality for instance, patient receiving chemotherapy and other immune          
modulating agent like glucocorticoids [5, 6].  
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Furthermore, a Radiopharmacy unit in developing African countries is classified under 2a              
international atomic energy agency Radiopharmacy classification, which restricts to     
handle white blood cell labeling.  
Therefore, there is need for a new agent at least as good as radiolabeled leukocyte, but 
easier to prepare, and without its inherent risks. Since there is a commercially introduced 
injectable form of human immunoglobulin (IgG) suitable for intravenous administration for 
the treatment of immunodeficiency syndrome, it is good to reconsider radiolabeling of IgG 
for immunodetection of infection and inflammation foci in the situation where the facility, 
equipment and personnel are not adequate and radiolabeled leukocyte is contraindicated. 
Radiolabeled IgG was previously used for the detection of infection and   inflammation 
foci, although it is less specific, radiolabeled IgG offers a simple and practical approach 
for early detection of acute focal infection. In addition, different authors used various tech-
niques for labeling antibodies and obtained promising results. 
The present study shows the approach how to formulate a radiopharmaceutical kit for the 
detection of infection and inflammation foci using human immunoglobulin G polyclonal 
antibody.  The kit labeled with 99mTc by direct and indirect methods.  
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2. LITERATURE REVIEW  
2.1. Mechanism of Infection and inflammation 
Infection is the invasion of an organism’s body tissues by pathogenic organisms such as 
bacteria, virus and fungi and their multiplication, and the reaction of host tissues to these 
organisms and the toxins they produce [7]. The body may react to infection through          
inflammation.  
Inflammation is the body’s response to infectious or noxious stimuli. The main aim of                
inflammation is to bring defense cells (immune cells) to the area of concern, as well as to         
inactivate or destroy invaders/pathogens and to begin repair [8].  Sometimes inflamma-
tory reaction may be initiated against normal body without any foreign agents and causes 
an autoimmune disease such as rheumatoid arthritis.  
Inflammation can be acute inflammation or chronic inflammation. When pathogens or any     
noxious agents infiltrate into the body and contact the tissue, a series of many responses 
by the body, particularly by the surrounding cells, will occur during inflammation. Many 
pathogens or inflammation-producing agents contain certain molecules, for instance 
many pathogenic bacteria express a protein molecule called PAMP, which is recognized 
by the immune cells in the body such as mast cells and macrophages.  When mast cells 
and macrophages recognize the foreign bodies/pathogens infiltrating into the body, they 
are triggered to release the inflammatory mediator, histamines and (cytokines, INF-α, & 
IL-1) respectively, which will cause vasodilation and increased vascular permeability [9].  
Vasodilation leads to greater blood flow to the area of inflammation, resulting in the   
movement of more immune cells to inflamed tissue, redness and heat. Whereas vascular 
permeability leads to endothelial cells becoming “leaky” from either direct endothelial cells 
or via chemicals mediators.  Another event that occurred during inflammation is exudation 
in which fluids, proteins, red blood cells, and white blood cells escape from the intravas-
cular space as a result of increased osmotic pressure extravascularly and increase hy-
drostatic pressure intravascularly.  
Cytokines also trigger repair by activating the fibroblast activity. The systemic effects       
associated with cytokines release from macrophage include a fever as well as leuco- 
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cytosis meaning the   accumulation of white blood cells circulating within the blood ves-
sels. Cytokines also promote the immigration of immune cells such as neutrophils and 
monocytes to the inflamed area. When the monocytes move from the blood vessels to 
the tissues, they become macrophages. 
As a consequence of vasodilation and vascular permeability, there will be vascular stasis, 
which means slowing of the blood in the blood stream with vasodilation and fluid               
exudation to allow chemical mediators and inflammatory cells to collect and respond to 
the stimulus. 
   
            
Figure 1: Steps of inflammatory response [8] 
 
Inflammation is normally controlled and self-limited. However, components of the              
inflammatory process may destroy normal tissue and inappropriate inflammatory            
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processes (autoimmune reaction) may lead to disorder [8]. 
Infectious and inflammatory diseases are the most common causes of mortality worldwide 
[10].  Rational diagnosis of infection and inflammation is invaluable for better outcome 
and overall costs of the disease management in which radiopharmaceuticals play an im-
portant role. Several radiopharmaceuticals have been developed in the last decade for 
infection and inflammation imaging [11]. Some of them have been used in clinical practice 
and many others are still in preclinical and clinical studies. Among the ligands for radio-
pharmaceuticals that used to detect infectious and inflammatory foci is human immuno-
globulin G polyclonal antibody. 
2.2. Immunioglobulin G 
Antibodies are highly specific proteins that are produced by plasma cells of the immune 
systems in response to pathogenic antigen. The primary function of an antibody is to bind 
to an antigen and label for its destruction.  Antibodies are also called immunoglobulins.  
There are five primary classes of immunoglobulins, namely IgG, IgM, IgA, IgD and IgE. 
These are distinguished by the type of heavy chain found in the molecule. IgG molecules 
have heavy chains known as gamma-chains; IgMs have mu-chains; IgAs have alpha-
chains; IgEs have epsilon-chains; and IgDs have delta-chains. 
Human immunoglobulin G (IgG) antibody is a monomeric glycoprotein and it consists of 
two identical heavy polypeptide chains (H) and two identical light polypeptide chains (L) 
joined via non-covalent interaction and covalent interchain disulfide bonds to form Y-
shaped structure [12].  Each chain is divided into variable (V) regions and constant (C) 
regions. A variable region contains specific types of amino acid sequence that can bind 
to specific antigen whereas the constant regions usually have constant amino acids se-
quences [13]. Each L chain consists of one variable domain, VL, and one constant do-
main, CL. The H chains consist of a variable domain, VH, and three constant domains 
CH1, CH2 and CH3. Each heavy chain has about twice the number of amino acids and 
molecular weight (~50.000) as each light chain (~25.000), resulting in a total immuno-
globulin monomer molecular weight of approximately 150,000. See Figure 2 below. 
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Figure 2: Generalized structure of an immunoglobulin (IgG). (Thermostat scientific) 
 
Human immunoglobulin G (IgG) is the most abundant class of Ig present in human serum. 
Produced as part of the secondary immune response to an antigen, this class of immu-
noglobulin constitutes approximately 75% of total serum Ig. IgG is the only class of Ig that 
can cross the placenta in humans, and it is largely responsible for the protection of a 
newborn during the first months of life. Because of its relative abundance and excellent 
specificity toward antigens, IgG is the principle antibody used in immunological research 
and clinical diagnostics.  
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IgG antibodies are extracted from donated blood plasma, commercially available and 
used to treat different immune related abnormalities such as immune deficiencies, auto-
immune disorders, and infection. The immunoglobulin G can be labelled with radionuclide 
directly and indirectly using bifunctional agents and used for imaging of infectious and 
inflammatory foci. The localization of the radiolabeled immunoglobulin G at the site of 
infectious and inflammatory foci is due to vascular permeability [14, 15]. 
2.3. Freeze drying process  
Freeze drying is a common method for preparing powdered pharmaceutical products for          
reconstitution before administration to the patients. The method is suitable for                 
thermolabile drug substances that cannot withstand the heat conditions used in other 
drying methods. This method has already been used successfully to prepare solid formu-
lations of biological and biotechnological drug products such as immunoglobulins and 
other proteins [16]. 
Different substances and formulations respond differently to the freeze drying conditions. 
As such, every freeze drying process should be tailored and optimized to every           par-
ticular formulation. An optimized freeze drying protocol is the one that yields the best 
product characteristics at the least cost. 
2.4. Radiopharmaceuticals for Infection and inflammation with the mechanism of              
accumulation 
Several radiopharmaceuticals have been developed to date for the diagnosis of infectious 
and inflammatory diseases.  The ideal radiopharmaceuticals for the imaging of infection 
and inflammation foci should have high sensitivity for infection/inflammation, differentiate 
between infection and inflammation, differentiate between acute and chronic infection, no 
toxicity and/or immunogenic response, minimum  radiation burden  to the patient and 
worker,  high specificity, rapid clearance from circulation, no uptake in gastrointestinal 
tract,  as well as they should be easy to prepare, have low cost and wide availability [11]. 
One of the oldest radionuclide to be used for imaging infection and inflammation was           
67Ga-citrate. Its localization at the site of infection and inflammation is likely to be due to 
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Ga3+ dissociating from citrate and chelating to blood transferrin. Then this complex      ex-
travasates to the site of inflammation due to increased capillary permeability. It also binds 
to lactoferrin and bacterial siderophores [17] that are abundant at the sites of            in-
flammation and infection. However, it has a limitation like long physical half-life, high en-
ergy gamma rays lead to poor quality image and high radiation absorbed dose, non-spe-
cific in infectious or sterile inflammations and at last not being available as a generator 
[18]. 
Because of the challenges associated with the radionuclide’s nuclear characteristics, 
there was need to explore other radionuclides with better radiation characteristics than 
gallium-67 (67Ga), which lead to the development of indium labeled radipharmaceuticals. 
Several ligands can be labelled with indium-111 and used for imaging infection and in-
flammation foci. Ligands such as human immunoglobulins G polyclonal antibody, mono-
clonal antibodies, white blood cells, streptavidin-biotin, bacterial chemotactic peptides 
and liposomes are among the examples. The main advantage of using indium to label 
with ligands for clinical application is its long half-life (67 hours) which allows imaging 
beyond 24 hr. post injection. 
However, suboptimal photon energies, low resolution images, long time from injection to     
imaging acquisition in the case of white blood cells [6]  and better imaging characteristics 
of technetium-99m for gamma camera (physical characteristics, availability, cost and 
lower radiation burden) challenges indium-111’s application in the detection of infection 
and inflammation foci [5]. 
Technetium-99m is a hugely advantageous radioisotope in infection and inflammation 
imaging because of the versatile technetium chemistry and its equally important nuclear 
properties. Since it is primarily available through a commercial GMP compliant generator, 
it is cheaper than many other radioisotopes used in radiopharmaceuticals such as the 
cyclotron produced radioisotopes. The 66-hour half-life of the parent molybdenum-99 ra-
dionuclide allows for a two-week working life of the generator, thereby allowing for effi-
cient supply logistics [19, 20]. 
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Nowadays 99mTc-hexamethylpropylene radiolabeled white blood cells (WBCs) is           
considered as a gold standard method for imaging infection and inflammation. The chem-
otactic properties of the activated leukocytes form the basis of labeled leukocyte imaging 
[5]. Unfortunately, the methods have drawbacks. Preparation is time consuming, labori-
ous, needs special facilities, carries a high risk of contamination and is contraindicated in 
some situations. 
Others ligands including antibodies and their fragments, antimicrobial peptides and anti-
biotics have been labelled with 99m technetium that avoid sophisticated methods of prep-
aration of labeled white blood cells but they are still not devoid of limitation and are non-
specific in differentiating infection and inflammation foci. 
Since SPECT technology generally has lower resolution and sensitivity than PET          
technology.  PET radiopharmaceuticals are also given significant interest in the area of     
infection and inflammation imaging. 18F-fluorodeoxyglucose (18F-FDG), the most           
commonly used PET radiopharmaceutical has been shown to target sites of infection via 
increased glucose utilization by infiltrated granulocytes and macrophages due to meta-
bolic requirements. However, this is nonspecific because 18F-FDG is also taken up at 
nonspecific sites of inflammation as well as sites of tumor [21]. Furthermore, the high cost 
and limited availability of PET imaging restrict its wide application in infection and               
inflammation imaging. 
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3. STATEMENT OF THE PROBLEM  
 
The unavailability of ideal radiopharmaceuticals limits the application of nuclear medicine 
in the diagnosis of infection and inflammatory disease.  
Radiolabeled Human Immunoglobulin G (HIG) may have some clinical utility, but long 
imaging time, and delayed blood pool clearance.  
Commercial kits unavailability limits its application.  
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4. OBJECTIVE  
4.1 General Objective  
 To formulate ready use cold kit of human immunoglobulin G (HIG) to be labelled with 
99mTc. 
4.2. Specific objectives  
 To determine optimum freeze-drying protocols for human immunoglobulin G contain-
ing   radiopharmaceuticals. 
 To compare direct and indirect labeling of human immunoglobulins G with Tc-99m 
 To determine the radiochemical purity of obtained radio labeled products 
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5. EXPERIMENTAL WORK 
5.1. Materials  
In our study we used the following chemicals:  
Human immunoglobulin G (HIG) solutions (50 g/L),  
Succinimidyl hydrazi–nonicotinic acid (HYNIC),  
Sodium Glucoheptonate,  
Sodium Pyrophosphate,  
1N HCl,  
1N NaOH,  
0.1N HCl,  
0.1N NaOH,  
tricine,  
Acetone,  
saline (0.9% Sodium Chloride),  
Ammonia,  
Ethanol (70%vol),  
Water for injection,  
Distilled water,  
0.15M acetate buffer (pH = 6.4),  
Phosphate buffered (PBS) saline (0.04 M, pH = 7.4),  
Stannous chloride dehydrate  
Gel filtration columns (Sephadex, 10mL, 25G and 50G). 
The equipment used to obtain our results was: 
Freeze Dryer (LBCONCO) 
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Vacuum pump  
Chromatogram scanner,  
ITLC paper, Test tubes,  
Tubes for ultra-filtration (AMICON) 
Centrifuge,  
UV-spectrometer,  
Filters (Millipore, 0.22 µm),  
Mo99/Tc99mgenerator (ELUMATIC II, IBA Molecular),  
Analytical balance (range, 1−20 mg),  
Autoclave,  
Oven,  
Refrigerator,  
Laminar airflow cabinet. 
 
 
5.2. Methods  
Purification of human immunoglobulins G (IgG) commercial preparation   
The purification of commercial preparation of IgG has been performed by pipetting the            
required amount of IgG solution into the ultrafiltration tube. Then, the solution was diluted 
to 2 mL with 0.04 M PBS (pH =7.4). The solution was ultra-filtered by spinning the tube at 
5000 rpm for one hour in centrifuge. The ultra-filtration process was repeated three times.   
Preparation of human immunoglobulin solutions 
Purified human immunoglobulin G (6 mg) was diluted to a concentration of 1 mg/mL      us-
ing 0.04 M phosphate buffer (pH = 7.4.0) in a 10mL type 1 glass vial. Aliquots (1 mL) of 
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the resulting solution were dispensed into 6 pre-sterilized pre-weighed 10 mL vials and 
re-weighed. The procedure was repeated for each freeze drying protocols.  
Freeze drying of IgG. 
The IgG preparation was freeze-dried using three different protocols as described below 
in the table. The freeze dryer was turned on and the chamber temperature was monitored 
until it was 4⁰C. The vial was loaded into the freeze dryer with a shelf temperature of 4°C 
and the process of freeze drying was started. After freeze drying, the vials were capped 
using rubber caps, blocked with an aluminum ring and stored in a fridge at 4⁰C. In Tables 
1, 2 and 3  the different freeze  drying  protocols are reported (Tables 1-3). 
Table 1: Three days’ lyophilization protocols 
Segment  Freezing temperature  RAMP  (Speed) Holding Time  
1(Pre-freezing) Room Temp to 40C 0.40C/min 30 minutes 
2 (Freezing)  40C to -450C 0.40C/min 3 hours  
-450C to -150C 0.150C/min 6 hours 
-150C to -450C 0.20C/min 2 hours  
3 (Primary Drying) -450C to -100c 0.150C/minute 28 hours  
4 (Secondary Drying)  -100C to 250c 0.150C/minute 14 hours  
 
 
Table 2: Two days’ lyophilization protocols  
Segment  Freezing temperature  RAMP (Speed) Holding Time  
1(Pre-freezing) Room Temp to 40C 1.00C/min 30 minutes 
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2 (Freezing)  40C to -450C 1.00C/min 5 hours   
3 (Primary Drying) -450C to -100c 0.150C/minute 28 hours  
4 (Secondary Drying)  -100C to 250c 0.20C/minute 14 hours  
Table 3: One day’s lyophilization protocols  
Segment  Freezing temperature  RAMP (Speed) Holding Time  
1(Freezing)  250C to-400c 10C/minute  5 hours  
2 (Primary Drying) -400C to -100c 0.120C/minute 4 hours  
3 (Secondary Drying)  -100C to 300c 0.080C/minute 2 hours  
 
Size exclusion Gel chromatography  
Preparation of sephadex gel G25 10mL column 
Sephadex G25 (10mg) powder was weighed in a balance to prepare 10 cm *1cm            
columns. It was submerged in distilled water in a glass beaker and left to swell overnight. 
The following day, the supernatant was decanted. The gel was packed into four BD® 
10mL syringes, washing the columns with 0.04 M phosphate buffer saline (pH=7.4) on 
every successive addition of gel until the desired level of 10mL was reached. The columns 
were saturated with 1mL of 0.1% BSA. The columns were each washed with 30mL 0.04 
M phosphate buffer (pH =7.4), sealed and stored at 4⁰C. The columns were preserved 
with 3mL of 0.2% sodium azide. 
 
Gel filtration of freeze-dried IgG from different protocols  
The freeze-dried product was reconstituted with 1mL saline solution. The reconstitution 
time was measured using a stopwatch and recorded.  The columns were kept at room 
temperature for one hour and then washed with 30mL 0.04 M phosphate buffer saline 
(pH=7.4). The number of drops from the column per mL of eluate was determined. The 
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saline solution of the freeze-dried product was then loaded onto the column and eluted 
using 0.04 M phosphate buffer saline (pH=7.4). The eluate was collected as 1mL           
fractions into 10 cuvettes. The absorbance of each cuvette was measured using a UV-
spectrometer at 280nm including the blank cuvette containing 1mL 0.04 M phosphate 
buffer saline (pH=7.4).  
 
Preparation of a lyophilized kit formulation for direct Tc-99m labeling  
A kit for direct labeling of human immunoglobulin G with technetium-99m was prepared as    
follows. Stannous chloride dehydrate (1 mg) and sodium pyrophosphate (or, alternatively,  sodium 
glucoheptonate) (8 mg) were placed in an evacuated vial and then dissolved in 16 mL of 1M HCl. 
From this vial, 4 mL were withdrawn and added to 1 mL of a purified IgG solution in PBS (5 
mg/mL) placed in a vial kept under constant vacuum. From the resulting mixture, 1 mL of solution 
was dispensed through a 0.22 µm sterile filter to another evacuated vial. Five final vials were 
obtained, which were stored in a freeze at low temperatures (- 200C) and then freeze-dried. 
 
Preparation of kit for indirect Tc-99m labeling  
 IgG-HYNIC conjugation  
The conjugation of IgG-HYNIC was done as follows: To a solution containing purified 
human immunoglobulin G (30mg/5ml), 0.5ml of 1M NaHCO3 and 3 molar folds of     
HYNIC (200µg) dissolved in 100 µl DMSO were added dropwise. The mixture was     in-
cubated at 18-250C for 30 min in the dark. The solution was ultra-filtered with sodium 
acetate 0.15 M (pH= 6.4) three times and applied to sephadex G-25M PD10 column and 
eluted with sodium acetate 0.15M (pH= 6.4). The eluent was collected in 1mL fraction in 
a cuvette and the eluent with high concentration was collected. The concentration of IgG 
was restored to 4 mg/mL with sodium acetate 0.15M (pH= 6.4). From the resulting mix-
ture, 0.5 mL of solution was dispensed through a 0.22 µm sterile filter to another evacu-
ated vial. Five final vials were obtained, which were stored in a freeze at low temperatures 
(- 200C) and then freeze-dried. 
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Preparation of Sn-Tricine kits  
Sn-Tricine kit was prepared by dissolving 400mg of tricin in 25 mL distilled water in evacuated 
vials. Then, 40 mg of SnCl2.2H2O dissolved in 1 mL of 1N HCl in evacuated vials was added to 
the tricine solution, the pH was adjusted to 5.3 with 0.8 mL 1 N NaOH.  The final volume was 
adjusted to 40 ml with saline. From the resulting solution, 1 mL was dispensed to five           
evacuated vials by passing through a 0.22µm filter, which were stored in a freeze at low 
temperatures   (- 200C) and then freeze-dried. 
 
Labeling of freeze-dried kits with Technetium-99m 
The labeling of all freeze-dried kits prepared by the described methods were labeled with 
99m Technetium using the eluate with containing 74 MBq and 740MBq (specific activity 
of the eluate). 
Sn-tricin kit was reconstituted with 5 ml saline solution. From this solution 50–60 μl was 
withdrawn and added to a vial containing HYNIC-IgG conjugate. Radiolabeling was       
performed by adding 20mCi of 99mTcO4-  in 2mL to the mixture and incubated for 30 min 
at room temperature.  
 
Determination of the radiochemical purity 
 The total volume of the labeled product was 2 ml. After labeling, we wanted to see the 
yield of the labeled product and the radiochemical purity.  
a. Direct labeling:   
The radiochemical purity of the radiolabeled IgG was assessed by instant thin-layer chro-
matography carried out on silica-gel plates (ITLC-SG) using saline as mobile phase.     Rf 
values of the radiolabeled IgG (99mTc-HIG) and of Tc-99m colloids ranged between 
0.0−0.1. Free 99mTcO4- and 99mTc-glucoheptonate/pyrophosphate were in the range of    
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0.9−1.0. Using acetone as a mobile phase, Rf  values of 99mTc-HIG and Tc-99m colloids 
fell in the interval of 0.0−0.1, whereas Rf values of free 99mTcO4- and 99mTc-
glucoheptonate/pyrophosphate were 1 and 0.0, respectively. Rf values are summarized 
in the following Table. 
 
Table 4: Mobile phase, stationary phase and Rf value for radiochemical purity test of   the 
direct labeled kit.  
Support  ITLC-SG ITLC-SG  
Solvent  Acetone Saline  
Rf 
99mTc-HIG 0.0-0.1 0.0-0.1 
Rf
99mTcO4
- 1.0 0.9-1.0 
Rf
99mTc-glucoheptonate/pyrophosphate 0.0 0.9-1.0 
 
b. Indirect labeling:  
The radiochemical purity of the indirectly labeled human immunoglobulin G (99mTc-
HYNIC-HIG) was analyzed by ITLC-SG using 0.15M citrate buffer (pH = 5.5) as the mo-
bile phase. Rf value of 99mTc-HYNIC-HIG was - were in the range of 0.0-0.25. These val-
ues for free 99mTcO4 and 99mTc-tricine and Tc-99m colloids were in the ranges of 0.7−1.0 
and 0.0−0.25, respectively. Then, ITLC-SG plates saturated with bovine serum albumin 
(BSA) were employed with EtOH:NH3:H2O (2:1:5) as the mobile phase. In this system, Rf 
values of 99mTc-HYNIC-HIG free 99mTcO4- and 99mTc-tricine were within the interval of 0.7-
1.0, whereas Tc-99m colloids ranged between 0.0-0.25. Rf values are summarized in the 
Table below. 
 
 
 
28 
 
Table 5: Mobile phase, stationary phase and Rf value for radiochemical purity test of the  
indirectly labeled kit.  
Support  ITLC-SG ITLC-SG saturated with 
1%BSA 
Solvent  0.15 citrate buffer, PH 5.5 ETOH: NH3: H2O (2:1:5) 
Rf 
99mTc-HYNIC-HIG 0.0-0.25 0.7-1.0 
Rf
99mTcO4
- and 99mTc -tricin 0.7-1.0 0.7-1.0 
Colloids  0.0-0.25 0.0-0.25 
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6. RESULTS 
Purification of human immunoglobulins G (IgG) commercial preparation   
The final concentration in mg/mL of the filtrate was calculated by measuring the                
absorbance of a sample of the filtered IgG at 280 nm in a UV spectrometer using molar 
attenuation coefficient of 1.4 L mol-1 cm-1. 
 
 
Figure 3: Size exclusion Gel chromatography (SEC) of IgG after purification.  
 
Freeze drying of IgG 
The IgG preparation was freeze-dried using three different protocols as described in ma-
terial and methods. The difference of the three compared protocols was the time of freeze 
drying that included the time of each segment of the process, speed (RAMP) and holding 
time. 
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We used only purified IgG to see which protocol is suitable for the kits containing              
Immunoglobulin G. The best protocol that we decided to use after the gel filtration of the 
freeze-dried IgG, dissolved in PBS, with the pH 7.4 (figures) was the two days’ protocol. 
 
 
 
 
 
 
 
 
Figure 4: The protocol for freeze drying providing the best results – two days’s protocol 
 
Effect of the process of freeze drying of human immunoglobulin 
We used all three protocols described in the material and methods and performed a      
comparison.  
 
a. Weight loss determination after 
The vials contacting IgG were weighed before and after freeze drying. The net loss is 
determined by subtracting the weight of the vials after freeze drying from the weight of 
vials before freeze drying.  
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Table 6: The weight loss of 1 mg/ml IgG after two days’ protocols lyophilization in open 
vials 
Vials  Weight of vial and 1mg/ml IgG Net loss 
Before freeze drying  After freeze drying 
1 10.708g 9.715g 0.993g 
2 10.662g 9.668g 0.994g 
3 10.692g 9.700g 0.992g 
4 10.607g 9.614g 0.993g 
5 10.868g 9.871g 0.997g 
6 10.765g 9.771g 0.994g 
7 (1.5ml) 11.245g 9.821g 1.424g 
 
 
Table 7:  The weight loss of 1mg/ml IgG after One day’s protocols lyophilization in open 
vials 
Vials  Weight of vial and 1mg/ml IgG Net loss 
 Before freeze drying  After freeze drying 
1 18.056g 17.066g 0.990g 
2 18.236g 17.229g 1.007g 
3 17.616g 16.622g 0.994g 
4 17.408g 16.404g 1.004g 
5 18.146g 17.147g 0.999g 
6 18.176g 17.255g 0.921g 
7 (1.5ml) 18.251g 17.172g 1.079g 
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We compared the weight loss from two protocols and we found that t critical (2.179) is 
greater than t calculated (0.8762). The weight loss from two days’ protocols is not  statis-
tically different from the weight loss from one-day freeze drying protocol.  
b. Velocity of the reconstruction for freeze-dried product  
The time taken to completely dissolve the constituents of the lyophilized products was 
recorded by a stopwatch in seconds.  The stopwatch was started when the solvent was 
introduced into the product and stopped when the complete dissolution was noticed by 
naked eye.  
 
Table 8: Time of reconstitution for freeze-dried IgG 
Sample  Time of reconstruction (s) 
Three days’ closed 25-48 
Two days’ closed  31-45 
Two days’ open 55-60 
One-day’ open  29-46 
 
c. Gel filtration 
We performed Gel filtration for each freeze-dried products. The antibody concentration in 
each cuvette was determined by using the absorbance from UV-visible spectrometer   us-
ing molar attenuation coefficient of 1.4 L mol-1 cm-1 against a blank cuvette containing 
1mL 0.04 M phosphate buffer saline (pH=7.4). The results were presented in a table and 
in a line graph spectrum. 
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Figure 5: Size exclusion Gel chromatography (SEC) of IgG 3-days’ freeze drying protocol 
using SEPHADEX Gel G25 Column  
 
 
Figure 6: Size exclusion Gel chromatography (SEC) of IgG 2-days’ freeze drying protocol 
using SEPHADEX Gel G25 Column 
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Figure 7: Size exclusion Gel chromatography (SEC) of IgG 1-day’ freeze drying protocol 
using SEPHADEX Gel G25 Column  
 
Preparation of a kit for direct labeling  
Kits for direct labeling contain purified human immunoglobulin G polyclonal antibody, 
stannous chloride dehydrate, and weak ligand sodium pyrophosphate or sodium             
gluconate. We freeze dried and checked for radiochemical purity. 
Preparation of a kit for indirect labeling  
The kit for indirect labeling was prepared using the described method. During the          
preparation, we used HYNIC as a bifunctional chelating agent. We performed gel              
filtration chromatography to separate the conjugate from unlabeled IgG and HYNIC.  See 
the graph below: 
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Conjugation of IgG -HYNIC 
 
Figure 8: SEC of IgG conjugated HYNIC before ultrafiltration 
 
Figure 9: SEC of IgG conjugated HYNIC after ultrafiltration 
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Preparation of Sn-Tricin kits  
Freeze drying of IgG containing kit  
For our kits prepared as explained in our methods and after testing the proposed methods 
of freeze drying - one day’, two days’ and three days’ protocols. We decided to use the 
two days’ protocol (Figure 4) for the reason that it provided us with more acceptable re-
sults. 
Labeling of freeze-dried kits with Technetium-99m 
The labeling of all freeze-dried kits prepared by the described methods was done with 
99m Technetium using the eluate with containing 74 MBq and 740 MBq (specific activity 
of the eluate 5.55 GBq/ml). 
The Sn-tricin kit was reconstituted with 5 ml saline solution.  From this solution 50–60 μl 
was withdrawn and added to a vial containing HYNIC-IgG conjugate. Radiolabeling was   
performed by adding 20mCi of 99mTcO4- in 2mL to the mixture and incubated for 30 min 
at room temperature.  
Determination of the radiochemical purity  
The total volume of the labeled product was 2 ml. After labeling, we wanted to see the 
yield of the labeled product and radiochemical purity. The radiochemical purity was          
realized 30 minutes after the labeling and 60 minutes after the labeling using the same 
solvents and material. 
Direct labeling: 
Radiochemical purity of the radiolabeled IgG was assessed by instant thin-layer            
chromatography as described in Material and methods.  
Indirect labeling:  
Radiochemical purity of the indirectly labeled human immunoglobulin G (99mTc-HYNIC-
HIG) as described in Material and methods. 
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Figure 10: Radiochromatogram of ITLC -SG as the stationary phase, acetone as the      
mobile phase and saline as the mobile phase for  Glucoheptonate containing a directly 
labeled kit. 
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Figure 11. Radiochemical purity of IgG HYNIC tricine performed by ITLC  
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Figure 11: Radiochromatogram of ITLC -SG as the stationary phase, acetone as the      
mobile phase and  saline as the mobile phase for  Pyrophosphate containing a directly 
labeled kit. 
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Figure 12: Radiochromatogram of ITLC -SG saturated with 1% BSA as the stationary 
phase, 0.15 citrate buffer, (pH =5.5) as the mobile phase  and ETOH: NH3: H2O (2:1:5) 
as the mobile phase for an indirectly labeled kit 
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7. DISCUSSION  
Human immunoglobulin G solutions as pharmaceutical products have already been avail-
able on the market for clinical practice. The commercial human immunoglobulin G prep-
aration contains different additives and preservatives apart from the human               im-
munoglobulin G antibody.  These additives and preservatives should be removed from 
the preparation to use the antibody for the preparation of the radiopharmaceuticals as 
these components may interfere with conjugation and radiolabeling of the IgG               
preparation.  A different purification technique of antibody can be used to remove this 
additive from the human immunoglobulin antibody solution such as dialysis, gel filtration 
chromatography, ion exchange chromatography and ultrafiltration. We found that             
the ultrafiltration purification technique is simple, easily available and cheap. We             
performed ultrafiltration until the antibody concentration of the filtrate was close to zero 
as measured in the UV-spectrometer at 280nm. 
Human immunoglobulin G containing radiopharmaceuticals kits in our preparation are 
usually in a concentration of 1mg/mL for direct labeling and 2mg/mL for indirect labeling. 
To compare the effects of different freeze drying protocols, we used a concentration of 
1mg/mL IgG solution. 
The stability of antibody containing radiopharmaceuticals in solution forms is usually low 
with long time storage. The development of stable, easily stored and shipped IgG          
containing radiopharmaceuticals requires the use of the freeze drying technology.       
However, the lyophilization process is costly, time consuming and may produce damage 
to the antibody. It is important to determine the optimal lyophilization protocols for our IgG 
preparation.  
The freeze drying of human immunoglobulin G for radiopharmaceutical kits for                
technetium-99m radiolabeling has already been done successfully [15]. The aim of our 
study was to compare the effectiveness of the reported freeze drying protocols with     
modified protocols so as to make recommendations on their suitability. The products were 
freeze dried using the IAEA recommended one-day protocol, two-day protocol and a 
three-day protocol.  
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We performed a comparison of lyophilization protocols using gel filtration chromatogram. 
Gel filtration is a popular method of analyzing liquid mixtures of substances that differ by 
their molecular masses. The gel is a bed with pores of defined sizes. Since they cannot 
pass through the pores, larger molecular mass substances readily navigate between the 
pores as they flow down and out of the bed as they elute earliest with minimal impedance. 
The substances with smaller masses, however, are small enough to go through most of 
the pores on their way down the bed. The motion of the smaller molecular mass sub-
stances is more retarded by the column packing, making them to elute later than the 
substances with higher molecular masses [22]. 
By collecting sequential fractions of the eluate and determination of the concentration of 
the substances in every eluate, it is possible to analyze the composition of the sample 
solution by molecular masses of the components. This method has been used previously 
in studies similar to ours to assess the amounts of immunoglobulin fractions in immuno-
globulin sample solutions [23]. 
In our study, it was important to analyze the immunoglobulin G solutions obtained from  
different freeze drying protocols so as to determine the concentration of immunoglobulin 
fragments in the mixtures. An inferior freeze drying protocol is expected to yield a freeze-
dried product upon reconstitution of which it produces a solution with high amounts of 
immunoglobulin fragments. From our results above, less immunoglobulin fragmentation 
was observed with the sample solution from the two-day protocol.  
Human immunoglobulin G ployclonal antibodies have been labeled with technetium in the 
two methods: direct and indirect methods.  Direct labeling methods require reduction of  
the antibody disulfide bond, so as to generate the thiosulfate functional groups where 
reduced technetium can bind to the antibody. We used the stannous chloride dehydrate 
as a reducing agent to reduce both the disulfide bond and the technetium. Stannous chlo-
ride dehydrate is widely available and demonstrated that it is the preferred reducing agent 
for technetium radiopharmaceuticals (Spies H 2007). The drawback with the direct 
method is that fragmentation of the antibody may occur and also technetium is unstable 
towards trans chelation.  
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On the other hand, the indirect method of technetium labeling of human immunoglobulin 
G employs the use of bifunctional agents which can attach very easily to the amino group 
of the antibody and the technetium. In our case, we use HYNIC bifunctional agents since-
HYNIC has been widely used as a bifunctional chelating agent for technetium -99m la-
beling with peptides and protein and it also forms strong bonds between technetium and 
the antibody. Tricine is important as a co-ligand to stabilize the Tc-HYNIC binding and the 
kit also contains stannous ion for reducing the technetium.   
Ultrafiltration and Gel filtration techniques were used for the purification of the IgG-HYNIC 
conjugate to remove any excess ligands, damaged and fragmented IgG antibody during 
conjugation, as shown in Figures 8 and 9. We first did size exclusion chromatography of 
the conjugated antibody using sephadex G-25M column and we observed that the graph 
of the concentration of antibody is not consistent with a multiple pick. Then we performed 
ultrafiltration on the conjugated product and after that we performed size exclusion gel 
chromatography and obtained a defined pick. We collected a cuvette with high concen-
tration and diluted with phosphate buffer saline 0.04 M (pH=7.4) to the concentration of 
4mg/ml, then 0.5 ml of the final solution was dispensed to evacuated vials passing through 
0.22µm filters to be lyophilized using the two-days’ protocols.  As we revealed, the two-
days’ protocol is a suitable lyophilization protocol for our products. 
We used the same activity to label kits for direct labeling and indirect labeling. The      tech-
netium-99m is obtained from IBA, molecular generators 99Mo/99mTc. The necessary 
quality control test was performed on technetium eluent before labeling.   We used an 
activity of 74MBq and 740MBq measured in the dose calibrators for labeling the kit. For 
direct methods, we used the onestep labeling methods; the activity in a volume of 2 mL 
was withdrawn from eluent vials and added to the kits. For indirect labeling, Sn-tricin kits 
were diluted with 5mL saline, then the 50-60 ul was withdrawn and added to the IgG 
HYNIC conjugate. Then technetium activity in 2mL was added. The solution was clear 
and free from particulate matter.  
One of the main quality control tests that should be performed on radiopharmaceuticals 
is radiochemical purity. We checked the radiochemical purity of our preparation using 
planar chromatography, which is time saving and easy to perform. ITLC SG as stationary 
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phase, by applying a drop of sample from the kit for direct labeling we developed two 
chromatogram strips, one for the acetone mobile phase and the other for the saline mobile 
phase.  
We were able to separate the radiochemical impurities, free pertechnetate and 99mTc-
glucoheptonate/pyrophosphate respectively.  The overall labeling efficiency was greater 
than 90%.  For indirect labeling, using ITLC SG as stationary phase and 0.15 citrate 
buffer, PH 5.5 as a mobile phase, we able to separate 99mTcO4- and 99mTc -tricin from 
99mTc-HYNIC-HIG, 99mTc-colloids. To determine the Tc- colloids content, we used ITLC 
SG saturated with bovine serum albumin as a stationary phase and ETOH: NH3: H2O 
(2:1:5) as a mobile phase.  The overall labeling efficiency was low. We observed a slow 
movement ETOH: NH3: H2O (2:1:5) on ITLC-SG saturated with BSA.  
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8. CONCLUSION  
Purification of the commercial IgG preparation before any subsequent procedure in the 
preparation of radiopharmaceuticals kits is important to remove any additives that may 
interfere with the labeling.   
From the study, different freeze drying protocols can be applied to freeze dry IgG but the 
two-days’ protocols give less antibody fragments than other protocols.   
Human immunoglobulin G can be labeled directly or indirectly using a bifunctional agent. 
Direct labeling of the prepared kit yields better labeling efficiency.  
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